Explore the latest lupus nephritis advances in this supplement, covering CAR-T therapy, obinutuzumab data & new diagnostic tools.
Rethinking Lupus Nephritis: Are Current Approaches & Guidelines off Target?
A rheumatologist & lupus expert reviews lupus nephritis treatment, questioning proteinuria cutoffs & ACR guidelines, advocating for newer therapies & end-of-treatment biopsies.
B Cell-Depleting Therapy in SLE & Lupus Nephritis
“B cells are central orchestraters of autoimmune disease by contributing to autoantibody production, antigen presentation and cytokine production,” says Georg Schett, MD, head of the Department of Medicine 3 (Rheumatology and Immunology) of the Friedrich-Alexander University Erlangen-Nürnberg, Germany. “B cells can be inhibited by monoclonal antibodies and chimeric antigen receptor (CAR) expressing cells.” Dr. Schett…
Why Target B Cells in SSc-ILD?
In a recent Arthritis & Rheumatology review article, three experts discuss the use of immunosuppressants to target B cells in a patient with systemic sclerosis-interstitial lung disease.
Management of Challenging Cases in Myositis
Immune mediated inflammatory myopathies represent a heterogenous group of diseases with variable degrees of multisystem involvement, including the skin, joints, lungs, and muscles. The ACR Convergence 2025 session, Management of Challenging Cases in Myositis, featured a case-based approach to highlight this complexity, guiding attendees through the nuances of diagnosis and management of antisynthetase syndrome, immune mediated necrotizing myopathy, and dermatomyositis.
Emerging Therapies for Antiphospholipid Syndrome, an Antibody-Mediated Disease
A recent A&R review explores innovative, emerging therapies for the currently incurable, antibody-mediated disease antiphospholipid syndrome.
Highlights from the European Congress of Internal Medicine
An overview of highlights from the 2025 ECIM meeting, including research on treatment options for systemic sclerosis, the management of PMR & autoimmune testing.
CAR-T Cells: Are We Closer to Drug-Free Remission Than We Think?
Most Sunday mornings, I make myself an exceptional cup of pour-over coffee and sit down on my deck with the latest issue of the New England Journal of Medicine. I check out the image of the week. I read the case report with pen in hand, racing to diagnose the patient before the authors spill…
CAR-T Cell Therapy in Autoimmune Disease: The Next Frontier
Chimeric antigen receptor (CAR) T cell therapy has the potential to fundamentally shift the treatment of autoimmune disease. During his presentation at EULAR 2024, Georg Schett, MD, provided an overview of this treatment process and described the promising findings of the latest research.
The Future of SLE Treatment?
Georg Schett, MD, presented the latest research into CAR T cell therapy for rheumatic diseases, such as systemic lupus erythematosus & other conditions. These findings demonstrate remarkable and durable efficacy for the treatment, as well as the potential for disease remission in some patients.